436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy
Nasopharyngeal carcinoma (NPC) is a malignancy with a distinct geographical distribution, showing high prevalence in Southeast Asia and Southern China. For patients with metastatic NPC that has progressed after two or more lines of chemotherapy, treatment options are historically limited and prognosis remains poor. While immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have revolutionized oncology, monotherapy often yields modest results in heavily pre-treated populations.
Recent clinical evidence suggests that dual blockade of the PD-1 and CTLA-4 pathways can provide synergistic effects, leading to improved response rates and survival. However, combining two separate monoclonal antibodies (such as nivolumab and ipilimumab) often increases the frequency and severity of immune-related adverse events. AK104 is a first-in-class bispecific antibody engineered to target both PD-1 and CTLA-4 within a single molecule, potentially offering the efficacy of dual blockade with a more favorable safety profile. This paper summarizes the initial results of the Phase II AK104-204 study.
Methodology
The AK104-204 trial (NCT04220307) is a multicenter, single-arm, open-label Phase II study evaluating the efficacy and safety of AK104 in patients with metastatic NPC.
Patient Population
Eligible participants included patients who had failed at least two prior lines of chemotherapy and were naive to anti-PD-1/PD-L1 therapies. At the time of this report, 23 patients were enrolled with a median age of 43 years. The cohort was predominantly male (87.0%), and the majority (73.9%) had an ECOG performance status of 1.
Treatment and Endpoints
Patients received AK104 at a dose of 6 mg/kg intravenously every two weeks until disease progression or unacceptable toxicity. The primary endpoint was the Objective Response Rate (ORR) as defined by RECIST v1.1. Secondary analyses included the Disease Control Rate (DCR) and safety assessments. Additionally, the study investigated the role of PD-L1 expression as a biomarker, using a Tumor Proportion Score (TPS) of 50% as the threshold for PD-L1 positivity.
Results
Efficacy and Biomarker Correlation
Of the 20 efficacy-evaluable patients, the confirmed ORR was 30% (6/20), and the DCR reached 70% (14/20). A significant correlation was observed between PD-L1 expression and clinical response:
PD-L1 Positive (TPS ≥ 50%): The ORR was 57.1% (4/7).
PD-L1 Negative (TPS < 50%): The ORR was 18.2% (2/11).
These findings suggest that while AK104 is active across different expression levels, patients with high PD-L1 expression derive substantially greater benefit from the bispecific blockade.
Safety Profile
AK104 demonstrated a manageable safety profile. Grade 3 treatment-related adverse events (TRAEs) occurred in 21.7% (5/23) of patients. Notably, no Grade 4 or Grade 5 TRAEs were reported, suggesting a potential safety advantage over traditional combination therapies. The most frequent TRAEs (incidence ≥ 20%) included:
Anaemia (30.4%)
Decreased white blood cell count (26.1%)
Hypothyroidism (26.1%)
Decreased neutrophil count (21.7%)
Rash (21.7%)
Discussion and Conclusion
The initial data from the AK104-204 study are encouraging, particularly for a patient population that has exhausted standard chemotherapy options. The 30% ORR in a third-line setting compares favorably to historical monotherapy data. Furthermore, the high response rate in the PD-L1 positive subgroup (57.1%) highlights the potential for AK104 to become a precision medicine tool for NPC.
While the results are promising, the study is limited by its small sample size (n=23) and single-arm design. Longer-term follow-up is required to assess the durability of these responses and the impact on progression-free and overall survival. Nevertheless, the favorable safety profile and anti-tumor activity support the further clinical development of AK104 as a therapeutic strategy for advanced nasopharyngeal carcinoma.
Summary updated
Abstract
<h3>Background</h3> Nasopharyngeal cancer (NPC) is common in Southeast Asia, especially in Southern China. Combination of CTLA-4 and PD-1 blockade has consistently demonstrated the increase of the response rates and survival rates of the patients (pts) compared to monotherapy in various tumors.<sup>1</sup> Dual CTLA-4/PD-1 blockade with ipilimumab plus nivolumab provided durable responses in patients with recurrent or metastatic NPC,<sup>2</sup> suggesting the combination of CTLA-4 and PD-1 blockers have synergistic effect in NPC. Here, this Phase II study present initial safety and efficacy data for AK104, a PD-1/CTLA-4 bispecific antibody, in metastatic NPC pts. <h3>Methods</h3> AK104-204 (NCT04220307) is a multicenter, single-arm, open-label study of AK104 in patients (pts) with metastatic NPC who have failed at least two lines of chemotherapy and didn’t receive any anti-PD-1/PD-L1 antibodies previously. All patients received AK104 6 mg/kg every 2 weeks until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Tumor proportion score (TPS)=50% was regarded as PD-L1 positive. <h3>Results</h3> As of 6 June 2021, 23 pts were enrolled. Median age was 43[range:19–64] years old, 87.0% was male, 73.9% ECOG performance status was 1. Of 20 efficacy-evaluable pts, the confirmed ORR was 30% (6/20); the disease control rate (DCR) was 70% (14/20). Among them, the ORR was 57.1% (4/7) in pts with PD-L1 positive and the 18.2% (2/11) in pts with PD-L1 negative. Grade 3 treatment-related adverse events (TRAEs) occurred in 21.7% (5/23) of pts. No Grade 4 or 5 TRAEs occurred. Most frequent TRAEs (incidence = 20%) were anaemia (30.4%), white blood cell count decreased (26.1%), hypothyroidism (26.1%), neutrophil count decreased (21.7%), and rash (21.7%). <h3>Conclusions</h3> AK104 demonstrated encouraging anti-tumor activity and favorable safety profile in pts with NPC who had disease progression after =2 prior lines of therapy. NPC pts with PD-L1–positive tumors receiving AK104 showed more benefits than those with PD-L1-negative tumors. AK104 for the treatment of NPC should be further evaluated. <h3>Acknowledgements</h3> Akeso Biopharma, Inc would like to thank the patients, investigators and site staff for their participation in this study. <h3>Trial Registration</h3> Clinical registration number: NCT04220307 <h3>References</h3> Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. <i>Journal of Experimental & Clinical Cancer Research</i> 2019, <b>38</b>(1): 1–12. <i>Annals of Oncology</i> 2020;<b>3</b>(suppl_6): S1347-S1354. 10.1016/annonc/annonc360. <h3>Ethics Approval</h3> This study received ethics approval from Ethics Committee of Sun Yat-Sen University Cancer Center on 04 Dec 2019 (Approval number: A2019-085-01). In accordance with ICH Good Clinical Practice Guidelines and the Declaration of Helsinki, study participants gave informed consent voluntarily before participating in this study. <h3>Consent</h3> Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
BibTeX
@inproceedings{mai2021phase,
author = {Hai‐Qiang Mai and Shaojun Lin and Dongping Chen and Xiaozhong Chen and Song Qu and Qin Lin and Ying Luo and Chunhong Hu and Dehua Wu and Tianxin Qin and Feng Jin and Nianyong Chen and Yunxiu Luo and Zhifang Yao and Xiaoping Jin and Baiyong Li and Yu Xia and Rui‐Hua Xu},
title = {{436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy}},
booktitle = {Regular},
year = {2021},
doi = {10.1136/jitc-2021-sitc2021.436},
}